The Australian Financial Complaints Authority (AFCA) ruled that Zurich’s denial of a trauma insurance claim was valid because the claimant’s bladder cancer met the policy’s specific exclusion for “carcinoma in situ.” This decision highlights how rigid policy definitions can conflict with serious medical diagnoses that require intensive treatment.
Why did AFCA uphold Zurich’s claim denial?
AFCA determined that the policy definition used by Zurich was unambiguous. The claimant, who was diagnosed with high-grade urothelial carcinoma of the bladder in September 2025, argued that his condition was too serious to be excluded. He noted that the illness required surgery, immunotherapy, and ongoing invasive surveillance.
However, Zurich denied the claim based on histopathology reports. According to the insurer, the reports showed the man had cancer in situ, which the policy specifically excluded. Zurich stated there was no evidence that the policy’s thresholds—uncontrollable growth, spread of malignant cells, and the destruction of normal tissue—had been met.
While AFCA acknowledged the cancer was serious and carried a risk of future invasion, the ombudsman ruled that the risk had not materialized at the time of the claim. Because the “carcinoma in situ” stage was explicitly excluded in the policy wording, the insurer was not obligated to pay the benefits.
How is medical technology changing insurance risks?
This ruling points to a growing tension between advancing medical diagnostics and actuarial insurance models. As medical screening becomes more sensitive, doctors can identify “in situ” cancers—cells that are abnormal but haven’t yet invaded surrounding tissue—much earlier than in previous decades.
This creates a potential “coverage gap” for consumers. A patient may undergo significant medical intervention, such as the immunotherapy mentioned in the AFCA case, yet remain ineligible for insurance payouts because their diagnosis technically falls under an excluded category.
Industry analysts suggest that as precision medicine improves, insurers may respond by further refining definitions to distinguish between “detectable” cancer and “clinically invasive” cancer. This could lead to more frequent disputes between policyholders and ombudsmen regarding what constitutes a “serious” condition.
What steps can consumers take to avoid coverage gaps?
To mitigate the risk of a denied claim, policyholders should move beyond general descriptions of coverage. Relying on a salesperson’s verbal assurance that a policy “covers all cancers” can be dangerous if the written definitions exclude specific stages.
Experts recommend the following actions to ensure better protection:
- Compare definitions: Check if different insurers define “cancer” using “invasion” or “destruction of tissue” as a requirement.
- Verify stage coverage: Confirm whether “carcinoma in situ” is included or excluded in the specific policy you are purchasing.
- Consult a specialist: Speak with an insurance broker who can interpret the technical language in a Product Disclosure Statement (PDS).
Frequently Asked Questions
What is the difference between invasive cancer and carcinoma in situ?
Invasive cancer has spread into the surrounding healthy tissue. Carcinoma in situ is considered a non-invasive stage where the abnormal cells are still contained within the original layer of tissue.
Can an ombudsman change an insurance company’s policy wording?
No. As seen in the AFCA ruling, the ombudsman interprets the existing wording. If the policy language is “unambiguous,” the ombudsman will generally uphold the insurer’s decision based on that text.
Why would an insurer exclude carcinoma in situ?
Insurers often exclude this stage because many in situ conditions are highly treatable and have a high survival rate, which impacts the actuarial risk calculations used to set premiums.
Have you ever encountered a dispute over insurance definitions? Share your thoughts in the comments below or subscribe to our newsletter for more industry insights.
